{
    "clinical_study": {
        "@rank": "65262", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: isavuconazole only", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of isavuconazole on Day 1"
            }, 
            {
                "arm_group_label": "Arm 2: isavuconazole + ketoconazole", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of isavuconazole on Day 4 and ketoconazole  twice daily (BID) for 24 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of ketoconazole at steady state on the\n      pharmacokinetics of a single dose of isavuconazole in healthy adult subjects."
        }, 
        "brief_title": "Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pharmacokinetics of Isavuconazole", 
            "Pharmacokinetics of Ketoconazole", 
            "Healthy Adult Volunteers"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject has a body weight of at least 45 kg and has a body mass index (BMI) of 18\n             to 32 kg/m2, inclusive\n\n          -  Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and\n             total bilirubin must not be above the  normal range\n\n          -  The female subject agrees to sexual abstinence, or is surgically sterile,\n             postmenopausal (defined as at least 2 years at Screening without menses), or using a\n             medically acceptable double barrier method (e.g. spermicide and diaphragm, or\n             spermicide and condom) to prevent pregnancy and agrees to continue using this method\n             from Screening until the end of the study; and is not lactating or pregnant as\n             documented by negative pregnancy tests at Screening and Day -1\n\n          -  The male subject agrees to sexual abstinence, is surgically sterile, or is using a\n             medically acceptable method to prevent pregnancy during the study period\n\n        Exclusion Criteria:\n\n          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac\n             arrhythmia or torsade de pointes, structural heart disease, or family history of Long\n             QT syndrome (suggested by sudden death of a close relative at a young age due to\n             possible or probable cardiac causes)\n\n          -  The subject has a positive result for hepatitis C antibodies or hepatitis B surface\n             antigen at Screening or is known to be positive for human immunodeficiency virus\n             (HIV)\n\n          -  The subject has a known or suspected allergy to any of the components of the trial\n             products or the azole class of compounds or a history of multiple and/or severe\n             allergies to drugs or foods (as judged by the investigator), or a history of severe\n             anaphylactic reactions\n\n          -  The subject is a smoker (any use of tobacco or nicotine containing products) within 6\n             months prior to Screening\n\n          -  The subject has had treatment with prescription drugs or complementary and\n             alternative medicines within 14 days prior to Day -1, or over-the-counter medications\n             within 1 week prior to Day -1, with the exception of occasionally use of ibuprofen\n\n          -  The subject has a recent history (within the last 2 years) of drug or alcohol abuse,\n             or a positive drug and/or alcohol screen"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657838", 
            "org_study_id": "9766-CL-0040"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1: isavuconazole only", 
                    "Arm 2: isavuconazole + ketoconazole"
                ], 
                "description": "oral", 
                "intervention_name": "Isavuconazole", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BAL4815", 
                    "BAL8557"
                ]
            }, 
            {
                "arm_group_label": "Arm 2: isavuconazole + ketoconazole", 
                "description": "oral", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketoconazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Isavuconazole", 
            "Ketoconazole", 
            "Healthy Volunteers", 
            "BAL8557", 
            "BAL4815"
        ], 
        "lastchanged_date": "August 2, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "West Bend", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53095"
                }, 
                "name": "Spaulding Clinical"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Open-Label, Two-Arm, Parallel Group Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Area under the concentration-time curve  from time of dosing to the last quantifiable concentration (AUClast) and  maximum concentration (Cmax)", 
            "measure": "Pharmacokinetic (PK) profile for isavuconazole (in plasma):  AUClast , Cmax", 
            "safety_issue": "No", 
            "time_frame": "Day 1 (Arm 1) and Day 4 (Arm 2): predose and 0.5, 1, 2, 4, 6, 8, 10, 12, 20, 24, 36, 48, 72, 96,120,144,168,192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480 and 504 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657838"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf), Time to attain Cmax (tmax), apparent body clearance after oral dosing (CL/F), apparent volume of distribution (Vz/F), and  apparent terminal elimination half-life (t1/2)", 
                "measure": "PK profile for isavuconazole (in plasma): AUCinf,  tmax, CL/F, Vz/F, and t1/2", 
                "safety_issue": "No", 
                "time_frame": "Day 1(Arm 1) and Day 4 (Arm 2): predose and 0.5, 1, 2, 4, 6, 8, 10, 12, 20, 24, 36, 48, 72, 96,120,144,168,192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480 and 504 hours post-dose"
            }, 
            {
                "measure": "PK  for ketoconazole (in plasma): trough concentration (Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "Day 2 (Arm 2): predose"
            }, 
            {
                "description": "AUC during time interval between consecutive dosing (AUCtau)", 
                "measure": "PK profile for ketoconazole (in plasma): AUCtau, Cmax, and tmax", 
                "safety_issue": "No", 
                "time_frame": "Days 3 and 4: predose and 0.5,1, 2, 4, 6, 8,12 and 24 hours post-dose"
            }, 
            {
                "measure": "Safety assessed by recording of adverse events, clinical laboratory evaluation, electrocardiograms (ECGs) and vital signs", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 25 (\u00b1 2 days)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Basilea Pharmaceutica International Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}